IL118581A - Optically crosslinked communication system - Google Patents

Optically crosslinked communication system

Info

Publication number
IL118581A
IL118581A IL11858196A IL11858196A IL118581A IL 118581 A IL118581 A IL 118581A IL 11858196 A IL11858196 A IL 11858196A IL 11858196 A IL11858196 A IL 11858196A IL 118581 A IL118581 A IL 118581A
Authority
IL
Israel
Prior art keywords
hif
communication system
hypoxia
purified
optically crosslinked
Prior art date
Application number
IL11858196A
Other languages
English (en)
Other versions
IL118581A0 (en
Original Assignee
Glynn Thomas William
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glynn Thomas William filed Critical Glynn Thomas William
Publication of IL118581A0 publication Critical patent/IL118581A0/xx
Publication of IL118581A publication Critical patent/IL118581A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Optical Communication System (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL11858196A 1995-06-06 1996-06-05 Optically crosslinked communication system IL118581A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/480,473 US5882914A (en) 1995-06-06 1995-06-06 Nucleic acids encoding the hypoxia inducible factor-1

Publications (2)

Publication Number Publication Date
IL118581A0 IL118581A0 (en) 1996-10-16
IL118581A true IL118581A (en) 2000-01-31

Family

ID=23908114

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11858196A IL118581A (en) 1995-06-06 1996-06-05 Optically crosslinked communication system

Country Status (9)

Country Link
US (3) US5882914A (fr)
EP (2) EP1806357A1 (fr)
JP (2) JPH11507541A (fr)
AT (1) ATE355299T1 (fr)
AU (1) AU704384B2 (fr)
CA (1) CA2222279C (fr)
DE (1) DE69636936T2 (fr)
IL (1) IL118581A (fr)
WO (1) WO1996039426A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
WO1998056936A1 (fr) * 1997-06-10 1998-12-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Sequences regulatrices impliquees dans l'expression genique regulee par l'hypoxie et leurs utilisations
US7074895B2 (en) 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
ATE293633T1 (de) * 1997-08-21 2005-05-15 Quark Biotech Inc Hypoxie-regulierte gene
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
CA2311643C (fr) 1997-12-04 2009-04-07 Genzyme Corporation Compositions et procedes induisant l'expression genique
JP2002507405A (ja) * 1998-03-27 2002-03-12 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 低酸素誘導ヒト遺伝子、タンパク質およびそれらの使用
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
AU5810999A (en) * 1998-08-27 2000-03-21 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
US6436654B1 (en) * 1998-11-13 2002-08-20 Pharmacia & Upjohn Ab Methods for identifying compounds that modulate HIF-1α
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants
ES2265948T3 (es) * 1999-06-14 2007-03-01 Cancer Research Technology Limited Terapia para el cancer.
AU7748200A (en) * 1999-09-30 2001-04-30 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
WO2001062965A2 (fr) * 2000-02-22 2001-08-30 Oxford Biomedica (Uk) Limited Procede d'analyse par expression differentielle
AU2001290179B2 (en) * 2000-08-07 2007-07-12 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
AU2002231223A1 (en) * 2000-10-26 2002-05-06 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US7919274B2 (en) 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US7176345B2 (en) * 2001-03-20 2007-02-13 Dana-Farber Cancer Institute, Inc. Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US7608698B2 (en) * 2001-05-23 2009-10-27 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
ATE432346T1 (de) * 2001-06-05 2009-06-15 Masahiro Hiraoka Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
WO2003074560A2 (fr) * 2002-03-05 2003-09-12 Angiogenetics Sweden Ab Residus critiques du facteur de transcription « -1alpha d'hypoxie inductible», produits et methodes associes
AU2003225495B2 (en) * 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
JP5578388B2 (ja) 2002-04-18 2014-08-27 オプコ ファーマシューティカルズ、エルエルシー 中枢神経システム及び／若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004042024A2 (fr) * 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania Compositions et procedes destines a l'inhibition par arnsi des hif-1 alpha
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
AU2003297062A1 (en) * 2002-12-11 2004-06-30 University Of Massachusetts METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
WO2004066949A2 (fr) 2003-01-28 2004-08-12 Rexahn Corporation Oligonucleotides anti-sens inhibant l'expression du hif-1
CA2513398C (fr) * 2003-01-31 2013-09-10 Rexahn Corporation Oligonucleotides anti-sens inhibant l'expression du hif-1
US20050148496A1 (en) * 2003-11-26 2005-07-07 Entelos, Inc. Treatment of rheumatoid arthritis with hypoxia inducible factor-1alpha antagonists
JP2007512847A (ja) * 2003-12-03 2007-05-24 アネシヴァ， インコーポレイテッド Ｈｉｆオリコヌクレオチドデコイ分子
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
DK1833840T3 (da) * 2004-11-09 2010-10-18 Santaris Pharma As Micromirs
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
CN100418574C (zh) * 2005-10-26 2008-09-17 王成球 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
PL2029742T3 (pl) 2006-06-07 2017-08-31 Genzyme Corporation Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego
US20080152654A1 (en) * 2006-06-12 2008-06-26 Exegenics, Inc., D/B/A Opko Health, Inc. COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
WO2008005533A2 (fr) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions et procédés de modification génétique de cellules ayant une fonction cosmétique pour l'amélioration de l'aspect cosmétique
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
DK2497500T3 (da) 2006-10-03 2017-01-02 Genzyme Corp Genterapi mod spinal muskelatrofi
NZ598092A (en) * 2008-02-14 2012-07-27 Lincoln University Methods and compositions comprising specific strains of trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
EP2361306A1 (fr) 2008-12-04 2011-08-31 OPKO Ophthalmics, LLC Compositions et procédés pour l'inhibition sélective d'isoformes pro-angiogéniques de vegf
PT3421603T (pt) 2009-05-02 2022-01-10 Genzyme Corp Terapia génica para distúrbios neurodegenerativos
CN102471769A (zh) 2009-07-17 2012-05-23 亚伦·T.·塔波尔 用于具有美容功能的细胞的遗传修饰以提高美容外观的方法和组合物
WO2011109427A2 (fr) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Amélioration de l'activité biologique de parni par modulation de son profil thermodynamique
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
JP6509745B2 (ja) * 2013-01-25 2019-05-08 エックスセル・バイオサイエンシズ・インコーポレイテッド 標的細胞の選択的富化のための方法、組成物、キット、及びシステム
ES2868305T3 (es) 2014-03-28 2021-10-21 Univ Washington Through Its Center For Commercialization Vacunas contra el cáncer de mama y de ovario
GB201601527D0 (en) 2016-01-27 2016-03-09 Univ Southampton Hif-1 and Hif-2 inhibitors
US20230212296A1 (en) * 2020-06-02 2023-07-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0479948B1 (fr) * 1989-06-23 1998-08-26 Genentech, Inc. Compositions et procedes destines a la synthese du recepteur b de la proteine natriuretique et procede d'utilisation
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1

Also Published As

Publication number Publication date
EP0833840A4 (fr) 2001-12-19
CA2222279C (fr) 2011-02-01
DE69636936D1 (de) 2007-04-12
US5882914A (en) 1999-03-16
EP1806357A1 (fr) 2007-07-11
CA2222279A1 (fr) 1996-12-12
US6222018B1 (en) 2001-04-24
JPH11507541A (ja) 1999-07-06
EP0833840A1 (fr) 1998-04-08
AU704384B2 (en) 1999-04-22
US6020462A (en) 2000-02-01
ATE355299T1 (de) 2006-03-15
AU6332696A (en) 1996-12-24
EP0833840B1 (fr) 2007-02-28
WO1996039426A1 (fr) 1996-12-12
IL118581A0 (en) 1996-10-16
DE69636936T2 (de) 2007-10-31
JP2009077729A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
IL118581A0 (en) Optically crosslinked communication system
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
EP0921785A4 (fr) Combinaison d'enzymes proteases acides et de tampons acides et son utilisation
GR3007092T3 (fr)
CA2009578A1 (fr) Antagonistes des recepteurs d'acide amine excitateur
AU1943388A (en) 3-indolepyruvic acid derivatives and pharmaceutical use thereof
DE69534468D1 (de) Wachstums-differenzierungsfaktor-11
EP0169016A3 (en) Polypeptide cartilage-inducing factors found in bone
CA2156024A1 (fr) Aminoacides synthetiques excitateurs
AU3009089A (en) Tetrazole excitatory amino acid receptor antagonists
EP0920501B8 (fr) La neuritine, un neurogene
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
FI880324A (fi) Foerfarande foer framstaellning av 4-tiazolidinkarboxylsyraderivat.
AU1795783A (en) New polypeptide from thymus glands
CA2006087A1 (fr) Polypeptides isoles a partir du venin d'une araignee : hololena curta
CS346591A3 (en) Complexes comprising s-(+)-phenylalkanoic acids and amino sugars
GR3023310T3 (en) Cyclopentanperhydrophenanthren-17beta-(3-furyl)-3-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders
AU6808190A (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
CA2004885A1 (fr) Peptides anticoagulant
AU569193B2 (en) Thymic humoral active peptides
EP0235904A3 (fr) Traitement de l'allergie avec la thymopentine
EP0596034A4 (fr) Purification du facteur neurotrophique ciliaire recombine et du facteur neurotrophique ciliaire tronque a terminaison c et procedes de traitement des lesions de nerfs peripheriques.
TW197410B (fr)
EP0147194A3 (en) Method and compositions for treating cerebral ischemia

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees